Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease

World Journal of Pediatrics

Volumn 6, Issue 1, 2010, Pages 13-31

  Suesaowalak, Monnipa ^a   Cleary, John P ^b   Chang, Anthony C ^b  

^a Pediatric Cardiac Surgery Foundation   (Thailand)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Children; Congenital heart disease; Endothelin receptor antagonist; Neonate; Nitric oxide; Phosphodiesterase inhibitor; Prostacyclin; Pulmonary arterial hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVIN RECEPTOR LIKE KINASE 1; AMBRISENTAN; BERAPROST; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; CITRULLINE; CLOPIDOGREL; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

ANEMIA; BLURRED VISION; BONE PAIN; CATHETER INFECTION; CATHETER MALFUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; EISENMENGER COMPLEX; ELECTROCARDIOGRAPHY; FLUSHING; FONTAN PROCEDURE; HEART OUTPUT; HUMAN; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; JAW PAIN; LIVER CELL DAMAGE; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OXYGEN SATURATION; PATHOPHYSIOLOGY; PHLEBOTOMY; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; SURVIVAL RATE; SYSTEMIC PULMONARY SHUNT; TERATOGENICITY; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; VISUAL IMPAIRMENT;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CHILD; CORONARY CIRCULATION; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; HEART CATHETERIZATION; HEART DEFECTS, CONGENITAL; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; LUNG TRANSPLANTATION; OXYGEN; PHOSPHODIESTERASE INHIBITORS; PHYSICAL EXAMINATION; RECEPTORS, ENDOTHELIN; RISK FACTORS;

EID: 76749128460     PISSN: 17088569     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12519-010-0002-9     Document Type: Review

References (148)

1. R.J. Barst 1999 Recent advances in the treatment of pediatric pulmonary artery hypertension Pediatr Clin North Am 46 331 345 1:STN:280: DyaK1M3jsVOjsw%3D%3D 10218078 10.1016/S0031-3955(05)70121-8 (Pubitemid 29177704)
2. R.J. Barst M. McGoon A. Torbicki O. Sitbon M.J. Krowka H. Olschewski, et al. 2004 Diagnosis and differential assessment of pulmonary arterial hypertension J Am Coll Cardiol 43 40S 47S 15194177 10.1016/j.jacc.2004.02.032 (Pubitemid 38759716)
3. H.W. Farber J. Loscalzo 2004 Mechanisms of disease: pulmonary arterial hypertension N Engl J Med 351 1655 1665 1:CAS:528:DC%2BD2cXos1Whtbg%3D 15483284 10.1056/NEJMra035488 (Pubitemid 39350426)
4. K. Ford 2005 Pulmonary artery hypertension: new drug treatment in children Arch Dis Child Ed Pract 90 ep15 ep20 10.1136/adc.2004.059113 (Pubitemid 40776466)
5. A. Widlitz R.J. Barst 2003 Pulmonary arterial hypertension in children Eur Respir J 21 155 176 1:STN:280:DC%2BD3s%2FlvFOrsg%3D%3D 12570125 10.1183/09031936.03.00088302 (Pubitemid 36150316)
6. I. Schulze-Neick J.E. Deanfield 2007 Pulmonary arterial hypertension in adults with congenital heart disease: general overview of disease mechanisms Adv Pulmonary Hypertens 6 121 125
7. R.M. Tulloh 2005 Congenital heart disease in relation to pulmonary hypertension in paediatric practice Paediatr Respir Rev 6 174 180 16153566 10.1016/j.prrv.2005.06.010 (Pubitemid 41258647)
8. G. Simonneau N. Galiè L.J. Rubin D. Langleben W. Seeger G. Domenighetti, et al. 2004 Clinical classification of pulmonary hypertension J Am Coll Cardiol 43 5S 12S 15194173 10.1016/j.jacc.2004.02.037 (Pubitemid 38759712)
9. Galiè N. Classification of patients with congenital systemicto-pulmonary shunts associated with pulmonary arterial hypertension: current status and future directions. In: Beghetti M, Barst RJ, Naeije R, Rubin LJ, eds. Pulmonary arterial hypertension related to congenital heart disease. Munich (Germany): Elsevier GmbH Deutschland, 2006: 11-17.
10. M.E. van Albada R.M. Berger 2008 Pulmonary arterial hypertension in congenital cardiac disease-the need for refinement of the Evian-Vanice classification Cardiol Young 18 10 17 18205971
11. I. Schulze-Neick M. Beghetti 2008 Classifying pulmonary hypertension in the setting of the congenitally malformed heart-cleaning up a dog's dinner Cardiol Young 18 22 25 18197998 10.1017/S1047951107001850 (Pubitemid 351228066)
12. D. Heath J.E. Edwards 1958 The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects Circulation 18 533 547 1:STN:280:DyaG1M%2Fgt12jsw%3D%3D 13573570
13. K. Nagumo S. Yamaki T. Takahashi 2000 Extremely thickened media of small pulmonary arteries in fatal pulmonary hypertension with congenital heart disease-a morphometric and clinicopathological study Jpn Circ J 64 909 914 1:STN:280:DC%2BD3M3ls1Ggtg%3D%3D 11194281 10.1253/jcj.64.909
14. M. Rabinovitch S.G. Haworth A.R. Castaneda A.S. Nadas L.M. Reid 1978 Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease Circulation 58 1107 1122 1:STN:280:DyaE1M%2Fktl2mtg%3D%3D 709766
15. M. Rabinovitch J.F. Keane W.I. Norwood A.R. Castaneda L. Reid 1984 Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects Circulation 69 655 667 1:STN:280:DyaL2c7jtVCnsA%3D%3D 6697454
16. W.F. Friedman M.F. Heiferman 1982 Clinical problems of postoperative pulmonary vascular disease Am J Cardiol 50 631 636 6214181 10.1016/0002-9149(82) 90332-0 (Pubitemid 13177399)
17. S.G. Haworth 1984 Pulmonary vascular disease in different types of congenital heart disease: implications for interpretation of lung biopsy findings in early childhood Br Heart J 52 557 571 1:STN:280: DyaL2M%2Fks12htg%3D%3D 6498033 10.1136/hrt.52.5.557
18. S. Yamaki M. Endo T. Takahashi 1997 Different grades of medial hypertrophy and intimal changes in small pulmonary arteries among various types of congenital heart disease with pulmonary hypertension Tohoku J Exp Med 182 83 91 1:STN:280:DyaK2szosFOlsw%3D%3D 9241775 10.1620/tjem.182.83
19. M.J. Landzberg 2007 Congenital heart disease associated pulmonary arterial hypertension Clin Chest Med 28 243 253 17338939 10.1016/j.ccm.2006.12. 004 (Pubitemid 46343760)
20. C.A. Wagenvoort 1980 Lung biopsy specimens in the evaluation of pulmonary vascular disease Chest 77 614 625 1:STN:280:DyaL3c7ls1ajug%3D%3D 7363679 10.1378/chest.77.5.614
21. S. Yamaki A. Abe M. Endo T. Tanaka K. Tabayashi T. Takahashi 1998 Surgical indication for congenital heart disease with extremely thickened media of small pulmonary arteries Ann Thorac Surg 66 1560 1564 1:STN:280: DyaK1M%2FptV2mtw%3D%3D 9875751 10.1016/S0003-4975(98)00776-0 (Pubitemid 29030152)
22. S. Yamaki A. Abe K. Tabayashi M. Endo H. Mohri T. Takahashi 1998 Inoperable pulmonary vascular disease in infants with congenital heart disease Ann Thorac Surg 66 1565 1570 1:STN:280:DyaK1M%2FptV2mtA%3D%3D 9875752 10.1016/S0003-4975(98)00779-6 (Pubitemid 29030153)
23. E.S. Egito V.D. Aiello I.B. Bosisio A.J. Lichtenfels A.L. Horta P.H. Saldiva, et al. 2003 Vascular remodeling process in reversibility of pulmonary arterial hypertension secondary to congenital heart disease Pathol Res Pract 199 521 532 14533936 10.1078/0344-0338-00457 (Pubitemid 37193074)
24. B. Alt R.H. Shikes 1983 Pulmonary hypertension in congenital heart disease: irreversible vascular changes in young infants Pediatr Pathol 1 423 434 1:STN:280:DyaL2M%2FjvVeisw%3D%3D 6687292 10.3109/15513818309025874
25. J.H. Newman J.A. Phillips 3rd J.E. Loyd 2008 Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies Ann Intern Med 148 278 283 18283205
26. K.E. Roberts J.J. McElroy W.P. Wong E. Yen A. Widlitz R.J. Barst, et al. 2004 BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Eur Respir J 24 371 374 1:CAS:528:DC%2BD2cXotlyrtL0%3D 15358693 10.1183/09031936.04.00018604 (Pubitemid 39232257)
27. A. Limsuwan O. Platoshyn Y. Yu L.J. Rubin A. Rothman J.X. Yuan 2001 Inhibition of K(+) channel activity in human pulmonary artery smooth muscle cells by serum from patients with pulmonary hypertension secondary to congenital heart disease Pediatr Res 50 23 28 1:CAS:528:DC%2BD3MXltFWrsrY%3D 11420414 10.1203/00006450-200107000-00007
28. M. Humbert N.W. Morrell S.L. Archer K.R. Stenmark M.R. MacLean I.M. Lang, et al. 2004 Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 13S 24S 1:CAS:528:DC%2BD2cXlsFyhtrs%3D 15194174 10.1016/j.jacc.2004.02.029 (Pubitemid 38759713)
29. G.P. Diller M.A. Gatzoulis 2007 Pulmonary vascular disease in adults with congenital heart disease Circulation 115 1039 1050 17325254 10.1161/CIRCULATIONAHA.105.592386 (Pubitemid 46328298)
30. Rosenzweig EB, Barst RJ. Clinical management of patients with pulmonary hypertension. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, eds. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1355-1368.
31. L. Daliento J. Somerville P. Presbitero L. Menti S. Brach-Prever G. Rizzoli, et al. 1998 Eisenmenger syndrome: factors relating to deterioration and death Eur Heart J 19 1845 1855 1:STN:280:DyaK1M7gtFyiuw%3D%3D 9886728 10.1053/euhj.1998.1046 (Pubitemid 28556655)
32. M. Gewillig 2005 The Fontan circulation Heart 91 839 846 15894794 10.1136/hrt.2004.051789 (Pubitemid 40769242)
33. M.A. Santos V.M. Azevedo 2004 Anomalous origin of one pulmonary artery from the ascending aorta. Surgical repair resolving pulmonary arterial hypertension Arq Bras Cardiol 83 503 507 15654447
34. Robinovitch M. Pathophysiology of pulmonary hypertension. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, eds. Moss and Adams' heart disease in infants, children, and adolescents including the fetus and young adult, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1322-1354.
35. L. Daliento L. Rebellato A. Angelini C. Frescura E. Mazzotti M. Rotundo, et al. 2002 Fatal outcome in Eisenmenger syndrome Cardiovasc Pathol 11 221 228 12140128 10.1016/S1054-8807(02)00105-9 (Pubitemid 34828274)
36. A.C. Chang D. Macrae 2009 Neonates with congenital cardiac defects and pulmonary hypertension Cardiol Young 19 Suppl1 4 7 19419598 10.1017/ S1047951109003874
37. Murphy AM, Neill CA, Zuckerberg AL. Syndromes and congenital heart defects. In: Nichols DG, Ungerleider RM, Spevak PJ, Greeley WJ, Cameron DE, Lappe DG, et al (eds). Critical heart disease in infants and children, 2nd ed. Philadelphia: Elsevier, 2006: 951-971.
38. L.J. Kajita E.E. Martinez J.A. Ambrose P.A. Lemos A. Esteves M. Nogueira da Gama, et al. 2001 Extrinsic compression of the left main coronary artery by a dilated pulmonary artery: clinical, angiographic, and hemodynamic determinants Catheter Cardiovasc Interv 52 49 54 1:STN:280:DC%2BD3M7isFWhtA%3D%3D 11146522 10.1002/1522-726X(200101)52:1<49::AID-CCD1012>3.0.CO;2-0 (Pubitemid 32066477)
39. Y. Piña J.E. Exaire J. Sandoval 2006 Left main coronary artery extrinsic compression syndrome: a combined intravascular ultrasound and pressure wire J Invasive Cardiol 18 E102 104 16495602
40. F.A. Paç D.N. Caǧdas M. Ulaş M.A. Ozatik M. Paç 2007 Left main coronary artery and aortic root compression associated with atrial septal defect and pulmonary hypertension Int J Cardiol 118 e41 43 17395318 10.1016/j.ijcard.2006.12.043 (Pubitemid 46601670)
41. M.D. McGoon G.C. Kane 2009 Pulmonary hypertension: diagnosis and management Mayo Clin Proc 84 191 207 19181654 10.4065/84.2.191
42. P.A. Randall E.R. Heitzman M.J. Bull E.M. Scalzetti S.K. Williams L.P. Gordon, et al. 1989 Pulmonary arterial hypertension: a contemporary review Radiographics 9 905 927 1:STN:280:DyaK3c%2FhvVGluw%3D%3D 2678297
43. T. Ryan O. Petrovic J.C. Dillon H. Feigenbaum M.J. Conley W.F. Armstrong 1985 An echocardiographic index for separation of right ventricular volume and pressure overload J Am Coll Cardiol 5 918 927 1:STN:280:DyaL2M7jt1egtw%3D%3D 3973294
44. S.G. Haworth 2008 The management of pulmonary hypertension in children Arch Dis Child 93 620 625 1:STN:280:DC%2BD1czpvVeguw%3D%3D 18381346 10.1136/adc.2007.120493 (Pubitemid 352030089)
45. C.J. Taylor G. Derrick A. McEwan S.G. Haworth M.R. Sury 2007 Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension Br J Anaesth 98 657 661 1:STN:280:DC%2BD2s3ks1CrtA%3D%3D 17401143 10.1093/bja/aem059 (Pubitemid 47072620)
46. M.J. Carmosino R.H. Friesen A. Doran D.D. Ivy 2007 Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization Anesth Analg 104 521 527 17312201 10.1213/01.ane.0000255732.16057.1c (Pubitemid 46309864)
47. M.I. Turanlahti P.O. Laitinen S.J. Sarna E. Pesonen 1998 Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension Heart 79 169 174 1:STN:280:DyaK1c7pvFWisA%3D%3D 9538311
48. R.A. Krasuski J.J. Warner A. Wang J.K. Harrison V.F. Tapson T.M. Bashore 2000 Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology J Am Coll Cardiol 36 2204 2211 1:CAS:528:DC%2BD3cXptFSqtbc%3D 11127462 10.1016/S0735-1097(00) 00994-3
49. T. Yasuda N. Tauchi R. Baba K. Nishibata T. Hatano S. Nakamura, et al. 1999 Inhalation of low-dose nitric oxide to evaluate pulmonary vascular reactivity in children with congenital heart disease Pediatr Cardiol 20 278 282 1:STN:280:DyaK1M3pvVemtA%3D%3D 10368453 10.1007/s002469900463 (Pubitemid 29279631)
50. B.C. Cannon T.F. Feltes J.K. Fraley R.G. Grifka E.M. Riddle J.P. Kovalchin 2005 Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response Pediatr Cardiol 26 565 569 1:STN:280:DC%2BD2MnptFWgtg%3D%3D 16132310 10.1007/s00246-004-0767-5 (Pubitemid 43015787)
51. M. Berner M. Beghetti I. Spahr-Schopfer I. Oberhansli B. Friedli 1996 Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease Am J Cardiol 77 532 535 1:STN:280:DyaK283gsV2rug%3D%3D 8629600 10.1016/S0002-9149(97)89353-8 (Pubitemid 26086648)
52. M.C. Post S. Janssens F. Van de Werf W. Budts 2004 Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension Eur Heart J 25 1651 1656 1:CAS:528:DC%2BD2cXntlOhsrc%3D 15351165 10.1016/j.ehj.2004.07.005 (Pubitemid 39209286)
53. J. Fujiyama Y. Yoshida H. Ogata T. Kato O. Kuteken K. Oyama 1984 Pulmonary wedge angiography for the evaluation of the pulmonary vascular bed in congenital heart disease Cathet Cardiovasc Diagn 10 237 246 1:STN:280: DyaL2M%2Fgt1SgsA%3D%3D 6478508 10.1002/ccd.1810100308
54. A. Grubstein O. Benjaminov D.B. Dayan D. Shitrit M. Cohen M.R. Kramer 2008 Computed tomography angiography in pulmonary hypertension Isr Med Assoc J 10 117 120 18432023
55. R. Sheehan J.K. Perloff M.C. Fishbein D. Gjertson D.R. Aberle 2005 Pulmonary neovascularity: a distinctive radiographic finding in Eisenmenger syndrome Circulation 112 2778 2785 16267251 10.1161/CIRCULATIONAHA.104.509869 (Pubitemid 41641671)
56. R.J. Barst J.R. Fineman M.A. Gatzoulis R.A. Krasuski 2007 Pulmonary hypertension roundtable: pulmonary arterial hypertension in adults with congenital heart disease Adv Pulmonary Hypertens 6 142 148
57. M. Humbert O. Sitbon G. Simonneau 2004 Treatment of pulmonary arterial hypertension N Engl J Med 351 1425 1436 1:CAS:528:DC%2BD2cXotVOrs7g%3D 15459304 10.1056/NEJMra040291 (Pubitemid 39302645)
58. V.V. McLaughlin D.E. Genthner M.M. Panella S. Rich 1998 Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension N Engl J Med 338 273 277 1:CAS:528: DyaK1cXpslaktA%3D%3D 9445406 10.1056/NEJM199801293380501 (Pubitemid 28065252)
59. A.E. Lammers A.A. Hislop Y. Flynn S.G. Haworth 2007 Epoprostenol treatment in children with severe pulmonary hypertension Heart 93 739 743 1:CAS:528:DC%2BD2sXntFOksr4%3D 17065181 10.1136/hrt.2006.096412 (Pubitemid 46808280)
60. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook: including neonatal dosing, drug administration, & extemporaneous preparations, 13th ed. Ohio: Lexi-Comp Inc., 2006.
61. Dent CL. Pulmonary hypertension in children. In: Burg FD, Ingelfinger JR, Polin RA, Gershon AA, eds. Current pediatric therapy, 18th ed. Philadelphia: Elsevier Inc., 2006: 503-510.
62. D.B. Badesch V.V. McLaughlin M. Delcroix C.D. Vizza H. Olschewski O. Sitbon, et al. 2004 Prostanoid therapy for pulmonary arterial hypertension J Am Coll Cardiol 43 56S 61S 1:CAS:528:DC%2BD2cXlsFyht74%3D 15194179 10.1016/j.jacc.2004.02.036 (Pubitemid 38759718)
63. V.F. Tapson M. Gomberg-Maitland V.V. McLaughlin R.L. Benza A.C. Widlitz A. Krichman, et al. 2006 Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial Chest 129 683 688 1:CAS:528:DC%2BD28XjtlGrt78%3D 16537868 10.1378/chest.129.3. 683
64. M. Gomberg-Maitland V.F. Tapson R.L. Benza V.V. McLaughlin A. Krichman A.C. Widlitz, et al. 2005 Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension Am J Respir Crit Care Med 172 1586 1589 16151039 10.1164/rccm.200505-766OC (Pubitemid 43076550)
65. M.H. Park 2008 Advances in diagnosis and treatment in patients with pulmonary arterial hypertension Catheter Cardiovasc Interv 71 205 213 18327839 10.1002/ccd.21389 (Pubitemid 351293767)
66. M.M. Hoeper M. Schwarze S. Ehlerding A. Adler-Schuermeyer E. Spiekerkoetter J. Niedermeyer, et al. 2000 Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue N Engl J Med 342 1866 1870 1:CAS:528:DC%2BD3cXksVCntL4%3D 10861321 10.1056/NEJM200006223422503 (Pubitemid 30419050)
67. D.D. Ivy A.K. Doran K.J. Smith G.B. Mallory Jr M. Beghetti R.J. Barst, et al. 2008 Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension J Am Coll Cardiol 51 161 169 1:CAS:528:DC%2BD1cXlsFCjtQ%3D%3D 18191742 10.1016/j.jacc.2007.09.031
68. A. Limsuwan P. Pienvichit P. Khowsathit 2005 Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease Pediatr Cardiol 26 787 791 1:STN:280:DC%2BD28%2FjsVSluw%3D%3D 16132278 10.1007/s00246-005-0925-4 (Pubitemid 43130171)
69. N. Galiè M. Humbert J.L. Vachiéry C.D. Vizza M. Kneussl A. Manes, et al. 2002 Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 39 1496 1502 11985913 10.1016/S0735-1097(02)01786-2 (Pubitemid 34439066)
70. R.J. Barst M. McGoon V. McLaughlin V. Tapson R. Oudiz S. Shapiro, et al. 2003 Beraprost therapy for pulmonary arterial hypertension J Am Coll Cardiol 41 2119 2125 1:CAS:528:DC%2BD3sXnvVSqsLs%3D 12821234 10.1016/S0735-1097(03)00463-7 (Pubitemid 36724255)
71. K. Durongpisitkul D. Jakrapanichakul D. Laohaprasitiporn J. Soongswang P. Chanthong A. Nana 2005 Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease J Med Assoc Thai 88 Suppl8 S60 65 16856428
72. S. Roux V. Breu S.I. Ertel M. Clozel 1999 Endothelin antagonism with bosentan: a review of potential applications J Mol Med 77 364 376 1:CAS:528:DyaK1MXjs1yitLg%3D 10353441 10.1007/s001090050363 (Pubitemid 29207019)
73. R.N. Channick O. Sitbon R.J. Barst A. Manes L.J. Rubin 2004 Endothelin receptor antagonists in pulmonary arterial hypertension J Am Coll Cardiol 43 62S 67S 1:CAS:528:DC%2BD2cXlsFyht7w%3D 15194180 10.1016/j.jacc.2004.02.042 (Pubitemid 38759719)
74. M. Yoshibayashi K. Nishioka K. Nakao Y. Saito M. Matsumura T. Ueda, et al. 1991 Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects Evidence for increased production of endothelin in pulmonary circulation. Circulation 84 2280 2285 1:STN:280:DyaK38%2FmvFygtA%3D%3D
75. I.H. Ozerol F.A. Pac E. Ozerol E. Ege S. Yologlu I. Temel, et al. 2004 Plasma endothelin-1, homocysteine and serum nitric oxide values in patients with left-to-right shunt Indian Heart J 56 653 657 15751522
76. L.J. Rubin D.B. Badesch R.J. Barst N. Galiè C.M. Black A. Keogh, et al. 2002 Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 896 903 1:CAS:528:DC%2BD38Xit1ekur0%3D 11907289 10.1056/NEJMoa012212 (Pubitemid 34984638)
77. S. Maiya A.A. Hislop Y. Flynn S.G. Haworth 2006 Response to bosentan in children with pulmonary hypertension Heart 92 664 670 1:CAS:528: DC%2BD28XkvF2jsL0%3D 16216850 10.1136/hrt.2005.072314
78. N. Gilbert Y.C. Luther O. Miera N. Nagdyman P. Ewert F. Berger, et al. 2005 Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children Z Kardiol 94 570 574 1:CAS:528:DC%2BD2MXhtFCnsr%2FN 16142516 10.1007/s00392-005-0266-6 (Pubitemid 41276477)
79. S. Rugolotto G. Errico R. Beghini S. Ilic C. Richelli E.M. Padovani 2006 Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia Minerva Pediatr 58 491 494 1:STN:280:DC%2BD28rnvV2lsA%3D%3D 17008861
80. J.K. Votava-Smith G.S. Perens J.C. Alejos 2007 Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt Pediatr Cardiol 28 314 316 1:STN:280: DC%2BD2svpvVyjtg%3D%3D 17563825 10.1007/s00246-007-0037-4 (Pubitemid 46976657)
81. M.A. Gatzoulis P. Rogers W. Li C. Harries D. Cramer S. Ward, et al. 2005 Safety and tolerability of bosentan in adults with Eisenmenger physiology Int J Cardiol 98 147 151 15676179 10.1016/j.ijcard.2004.08.025 (Pubitemid 40169865)
82. I. Schulze-Neick N. Gilbert R. Ewert C. Witt E. Gruenig B. Enke, et al. 2005 Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy Am Heart J 150 716 16209972
83. R.L. Benza B.K. Rayburn J.A. Tallaj C.S. Coffey L.J. Pinderski S.V. Pamoukian, et al. 2006 Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease Chest 129 1009 1015 1:CAS:528:DC%2BD28XkslensL4%3D 16608951 10.1378/chest.129.4.1009
84. O. Sitbon M. Beghetti J. Petit L. Iserin M. Humbert V. Gressin, et al. 2006 Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects Eur J Clin Invest 36 Suppl3 25 31 1:CAS:528:DC%2BD28XhtVeqtL3I 16919007 10.1111/j.1365-2362.2006.01685.x (Pubitemid 44179778)
85. R. Ibrahim J.T. Granton S. Mehta 2006 An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease Can Respir J 13 415 420 17149459
86. M. D'Alto C.D. Vizza E. Romeo R. Badagliacca G. Santoro R. Poscia, et al. 2007 Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart 93 621 625 17135220 10.1136/hrt.2006.097360 1:CAS:528:DC%2BD2sXls12ktbo%3D (Pubitemid 46707118)
87. G.P. Diller K. Dimopoulos M.G. Kaya C. Harries A. Uebing W. Li, et al. 2007 Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease Heart 93 974 976 1:CAS:528:DC%2BD2sXpsFartbw%3D 17639112 10.1136/hrt.2006.089185 (Pubitemid 47122051)
88. E. Kotlyar R. Sy A.M. Keogh F. Kermeen P.S. Macdonald C.S. Hayward, et al. 2006 Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease Cardiol Young 16 268 274 16725066 10.1017/S1047951106000114 (Pubitemid 44269416)
89. K. Durongpisitkul D. Jakrapanichakul S. Sompradikul 2008 A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease J Med Assoc Thai 91 196 202 18389984
90. R.L. van Loon E.S. Hoendermis M.G. Duffels A. Vonk-Noordegraaf B.J. Mulder H.L. Hillege, et al. 2007 Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 154 776 782 17893008 10.1016/j.ahj.2007.06.003 1:CAS:528:DC%2BD2sXhtVOit7jP (Pubitemid 47429578)
91. S.C. Apostolopoulou A. Manginas D.V. Cokkinos S. Rammos 2007 Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart 93 350 354 1:CAS:528:DC%2BD2sXjvFSjsbY%3D 16980516 10.1136/hrt.2006.100388 (Pubitemid 46579526)
92. N. Galiè M. Beghetti M.A. Gatzoulis J. Granton R.M. Berger A. Lauer, et al. 2006 Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebocontrolled study Circulation 114 48 54 16801459 10.1161/CIRCULATIONAHA.106.630715 1:CAS:528:DC%2BD28XmtFegs7o%3D (Pubitemid 44305274)
93. N. Galiè L.J. Rubin M.M. Hoeper P. Jansa H. Al-Hiti G.M. Meyer, et al. 2008 Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY) study: a doubleblind, randomised, controlled trial Lancet 371 2093 2100 18572079 10.1016/S0140-6736(08)60919-8 (Pubitemid 351902178)
94. R.J. Barst D. Ivy J. Dingemanse A. Widlitz K. Schmitt A. Doran, et al. 2003 Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Clin Pharmacol Ther 73 372 382 1:CAS:528:DC%2BD3sXjtFWntbs%3D 12709727 10.1016/S0009-9236(03)00005-5 (Pubitemid 36403597)
95. R.J. Barst D. Langleben A. Frost E.M. Horn R. Oudiz S. Shapiro, et al. 2004 Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 441 447 14630619 10.1164/rccm.200307-957OC
96. R.J. Barst D. Langleben D. Badesch A. Frost E.C. Lawrence S. Shapiro, et al. 2006 Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan J Am Coll Cardiol 47 2049 2056 1:CAS:528:DC%2BD28XksFalsbs%3D 16697324 10.1016/j.jacc.2006.01.057
97. D. Langleben A.M. Hirsch E. Shalit L. Lesenko R.J. Barst 2004 Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 126 1377 1381 1:CAS:528: DC%2BD2cXhtValur3E 15486408 10.1378/chest.126.4.1377 (Pubitemid 39391276)
98. R.L. Benza S. Mehta A. Keogh E.C. Lawrence R.J. Oudiz R.J. Barst 2007 Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan J Heart Lung Transplant 26 63 69 17234519 10.1016/j.healun.2006.10.019 (Pubitemid 46096748)
99. N. Galiè D. Badesch R. Oudiz G. Simonneau M.D. McGoon A.M. Keogh, et al. 2005 Ambrisentan therapy for pulmonary arterial hypertension J Am Coll Cardiol 46 529 535 16053970 10.1016/j.jacc.2005.04.050 1:CAS:528: DC%2BD2MXmvVKnsrk%3D (Pubitemid 41040298)
100. N. Galiè H.A. Ghofrani A. Torbicki R.J. Barst L.J. Rubin D. Badesch, et al. 2005 Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2148 2157 16291984 10.1056/NEJMoa050010 (Pubitemid 41653106)
101. S.S. Kothari B. Duggal 2002 Chronic oral sildenafil therapy in severe pulmonary artery hypertension Indian Heart J 54 404 409 12462669
102. I. Raposo-Sonnenfeld I. Otero-González M. Blanco-Aparicio Ferrer-Barba C. Medrano-López 2007 Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome Rev Esp Cardiol 60 366 372 17521545 10.1157/13101640 (Pubitemid 46881542)
103. A. Giardini A. Balducci S. Specchia G. Gargiulo M. Bonvicini F.M. Picchio 2008 Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients Eur Heart J 29 1681 1687 1:CAS:528: DC%2BD1cXpt1CqsLc%3D 18534975 10.1093/eurheartj/ehn215 (Pubitemid 351957545)
104. F. Peiravian A.A. Amirghofran M. Borzouee G.H. Ajami M.R. Sabri S. Kolaee 2007 Oral sildenafil to control pulmonary hypertension after congenital heart surgery Asian Cardiovasc Thorac Ann 15 113 117 17387192
105. S.G. Raja M.D. Danton K.J. MacArthur J.C. Pollock 2007 Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects J Cardiothorac Vasc Anesth 21 203 207 1:CAS:528:DC%2BD2sXlsVOisrc%3D 17418732 10.1053/j.jvca.2006. 02.010 (Pubitemid 46528282)
106. L. Kovacikova M. Zahorec M. Nosal 2007 Sildenafil as a pulmonary vasodilator after repair of congenital heart disease Bratisl Lek Listy 108 453 454 1:CAS:528:DC%2BD1cXitVGqt7Y%3D 18306725
107. P. Namachivayam U. Theilen W.W. Butt S.M. Cooper D.J. Penny L.S. Shekerdemian 2006 Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children Am J Respir Crit Care Med 174 1042 1047 1:CAS:528:DC%2BD28Xht1Oksr7I 16917115 10.1164/rccm.200605-694OC (Pubitemid 44684454)
108. I. Schulze-Neick P. Hartenstein J. Li B. Stiller N. Nagdyman M. Hübler, et al. 2003 Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease Circulation 108 Suppl1 II167 173 12970227
109. A.E. Lammers S.G. Haworth C.M. Pierce 2006 Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption Cardiol Young 16 84 86 16454884 10.1017/S1047951105002155 (Pubitemid 43203366)
110. A.A. Karatza A. Bush A.G. Magee 2005 Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension Int J Cardiol 100 267 273 15823634 10.1016/j.ijcard.2004.09.002
111. S. Noori P. Friedlich P. Wong A. Garingo I. Seri 2007 Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension Neonatology 91 92 100 1:CAS:528: DC%2BD2sXjtFyguro%3D 17344658 10.1159/000097125 (Pubitemid 46272384)
112. F. Murad 2006 Nitric oxide and cyclic GMP in cell signaling and drug development N Engl J Med 355 2003 2011 1:CAS:528:DC%2BD28XhtFymur3J 17093251 10.1056/NEJMsa063904 (Pubitemid 44708019)
113. J.D. Waldman J.J. Lamberti J.W. Mathewson S.E. Kirkpatrick S.W. Turner L. George, et al. 1983 Congenital heart disease and pulmonary artery hypertension. I. Pulmonary vasoreactivity to 15% oxygen before and after surgery J Am Coll Cardiol 2 1158 1164 1:STN:280:DyaL2c%2FjtlOgtA%3D%3D 6226728
114. F. Kotake J. Kobayashi M. Sonoda T. Komoda 2000 Nitric oxiderelated compounds in patients with congenital heart defects and pulmonary hypertension Pediatr Int 42 249 254 1:CAS:528:DC%2BD3cXkvFGrsrw%3D 10881580 10.1046/j.1442-200x.2000.01219.x (Pubitemid 30409337)
115. P. Kiettisanpipop P. Lertsapcharorn P. Chotivittayatarakorn Y. Poovorawan 2007 Plasma levels of nitric oxide in children with congenital heart disease and increased pulmonary blood flow J Med Assoc Thai 90 2053 2057 18041423
116. D. Journois P. Pouard P. Mauriat T. Malhère P. Vouhé D. Safran 1994 Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects J Thorac Cardiovas Surg 107 1129 1135 1:STN:280:DyaK2c3htV2hsw%3D%3D
117. M. Beghetti W. Habre B. Friedli M. Berner 1995 Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients Br Heart J 73 65 68 1:STN:280: DyaK2M7psVOksQ%3D%3D 7888265 10.1136/hrt.73.1.65
118. A.P. Goldman R.E. Delius J.E. Deanfield D.J. Macrae 1995 Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations Ann Thorac Surg 60 300 305 1:STN:280:DyaK2MznsVSksQ%3D%3D 7646090 10.1016/0003-4975(95)00408-D
119. H. Shimpo Y. Mitani J. Tanaka T. Mizumoto K. Onoda K. Tani, et al. 1997 Inhaled low-dose nitric oxide for postoperative care in patients with congenital heart defects Artif Organs 21 10 13 1:CAS:528:DyaK2sXnvFaqsQ%3D%3D 9012898
120. I.A. Russell M.S. Zwass J.R. Fineman M. Balea K. Rouine-Rapp M. Brook, et al. 1998 The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease Anesth Analg 87 46 51 1:CAS:528:DyaK1cXks1GksL0%3D 9661544 10.1097/00000539-199807000-00011 (Pubitemid 28311609)
121. K.S. Murthy S.G. Rao K.S. Prakash C. Robert S. Dhinakar K.M. Cherian 1999 Role of inhaled nitric oxide as a selective pulmonary vasodilator in pediatric cardiac surgical practice Indian J Pediatr 66 357 361 1:STN:280: DC%2BD3c3lvVCiug%3D%3D 10798083 10.1007/BF02845523
122. S. Göthberg K.E. Edberg 2000 Inhaled nitric oxide to newborns and infants after congenital heart surgery on cardiopulmonary bypass A dose-response study. Scan Cardiovasc J 34 154 158
123. R.W. Day J.A. Hawkins E.C. McGough K.L. Crezeé G.S. Orsmond 2000 Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease Ann Thorac Surg 69 1907 1912 1:STN:280: DC%2BD3czkvFSgtg%3D%3D 10892945 10.1016/S0003-4975(00)01312-6 (Pubitemid 30445541)
124. R. Sharma N. Raizada S.K. Choudhary A. Bhan P. Kumar R. Juneja, et al. 2001 Does inhaled nitric oxide improve survival in operated congenital disease with severe pulmonary hypertension? Indian Heart J 53 48 55 1:STN:280: DC%2BD3MvgsFGgtw%3D%3D 11456141
125. G. Pérez-Peñate P. Cabrera Navarro M. Ponce González E. Górriz Gómez J. Pulido Duque A. García Quintana, et al. 2005 Long-term inhaled nitric oxide plus dipyridamole for pulmonary arterial hypertension Respiration 72 419 422 16088287 10.1159/000086258 1:CAS:528:DC%2BD2MXntFSmtLs%3D (Pubitemid 41160177)
126. P. Goyal U. Kiran S. Chauhan R. Juneja M. Choudhary 2006 Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease Br J Anaesth 97 208 214 1:CAS:528: DC%2BD28XosFaiu7g%3D 16707530 10.1093/bja/ael112 (Pubitemid 44295707)
127. H.A. Omar F. Gong M.Y. Sun S. Einzig 1999 Nebulized nitroglycerin in children with pulmonary hypertension secondary to congenital heart disease W V Med J 95 74 75 1:STN:280:DyaK1M3jtVOisg%3D%3D 10214095
128. D.J. Levine 2006 Diagnosis and management of pulmonary arterial hypertension: implications for respiratory care Respir Care 51 368 381 16563191
129. E.B. Rosenzweig D.D. Ivy A. Widlitz A. Doran L.R. Claussen D. Yung, et al. 2005 Effects of long-term bosentan in children with pulmonary arterial hypertension J Am Coll Cardiol 46 697 704 1:CAS:528:DC%2BD2MXns1Whurw%3D 16098438 10.1016/j.jacc.2005.01.066 (Pubitemid 41132700)
130. H.A. Ghofrani F. Rose R.T. Schermuly H. Olschewski R. Wiedemann A. Kreckel, et al. 2003 Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 158 164 1:CAS:528:DC%2BD3sXmtVOisrY%3D 12849677 10.1016/S0735-1097(03)00555-2 (Pubitemid 36760778)
131. K. Lunze N. Gilbert S. Mebus O. Miera W. Fehske F. Uhlemann, et al. 2006 First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension Eur J Clin Invest 36 Suppl3 32 38 1:CAS:528:DC%2BD28XhtVeqtL3J 16919008 10.1111/j.1365-2362.2006.01692.x (Pubitemid 44179779)
132. R. Channick T.L. Williamson 2004 Diagnosis and treatment of pulmonary arterial hypertension Cardiol Clin 22 441 452 15302363 10.1016/j.ccl.2004.04.004 (Pubitemid 39078425)
133. I.M. Robbins S.M. Kawut D. Yung M.P. Reilly W. Lloyd G. Cunningham, et al. 2006 A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension Eur Respir J 27 578 584 1:CAS:528:DC%2BD28XjtVKqur8%3D 16507859 10.1183/09031936.06.00095705 (Pubitemid 43372533)
134. F.E. Barr H. Beverley K. VanHook E. Cermak K. Christian D. Drinkwater, et al. 2003 Effect of cardiopulmonary bypass on urea cycle intermediates and nitric oxide levels after congenital heart surgery J Pediatr 142 26 30 1:CAS:528:DC%2BD3sXhtVChsr4%3D 12520250 10.1067/mpd.2003.mpd0311 (Pubitemid 36106383)
135. H.A. Smith J.A. Canter K.G. Christian D.C. Drinkwater F.G. Scholl B.W. Christman, et al. 2006 Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline J Thorac Cardiovasc Surg 132 58 65 1:CAS:528:DC%2BD28XnslKgtbc%3D 16798303 10.1016/j.jtcvs.2006.02.012 (Pubitemid 43913824)
136. F.E. Barr R.G. Tirona M.B. Taylor G. Rice J. Arnold G. Cunningham, et al. 2007 Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension J Thorac Cardiovasc Surg 134 319 326 1:CAS:528:DC%2BD2sXhtVWiurrO 17662768 10.1016/j.jtcvs.2007.02.043 (Pubitemid 47088581)
137. W. Klepetko E. Mayer J. Sandoval E.P. Trulock J.L. Vachiery P. Dartevelle, et al. 2004 Interventional and surgical modalities of treatment for pulmonary arterial hypertension J Am Coll Cardiol 43 73S 80S 15194182 10.1016/j.jacc.2004.02.039 (Pubitemid 38759721)
138. M.J. Landzberg 2007 Emerging therapy of congenital heart disease associated with pulmonary hypertension Adv Pulmonary Hypertens 6 136 141
139. I.U. Khan I. Ahmed W.A. Mufti A. Rashid A.A. Khan S.A. Ahmed, et al. 2006 Ventricular septal defect in infants and children with increased pulmonary vascular resistance and pulmonary hypertension-surgical management: leaving an atrial level communication J Ayub Med Coll Abbottabad 18 21 25
140. R. Larios E.A. Fitch G. Blanco C.P. Bailey 1959 The use of an artificial foraminal valve prosthesis in the closure of interatrial and interventricular septal defect Dis Chest 36 631 641 1:STN:280:DyaF3c7ms1yltg%3D%3D 14414199
141. W.M. Novick A.T. Gurbuz D.C. Watson V.V. Lazorishinets A.N. Perepeka I. Malcic, et al. 1998 Double patch closure of ventricular septal defect with increased pulmonary vascular resistance Ann Thorac Surg 66 1533 1538 1:STN:280:DyaK1M%2FptV2msw%3D%3D 9875747 10.1016/S0003-4975(98)00956-4 (Pubitemid 29030148)
142. W.M. Novick N. Sandoval V.V. Lazorhysynets V. Castillo A. Baskevitch X. Mo, et al. 2005 Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance Ann Thorac Surg 79 21 28 15620908 10.1016/j.athoracsur.2004.06.107 (Pubitemid 40037432)
143. A. Afrasiabi M. Samadi H. Montazergaem 2006 Valved patch for ventricular septal defect with pulmonary arterial hypertension Asian Cardiovasc Thorac Ann 14 501 504 17130327
144. B. Zhang S. Wu J. Liang G. Zhang G. Jiang M. Zhou, et al. 2007 Unidirectional monovalve homologous aortic patch for repair of ventricular septal defect with pulmonary hypertension Ann Thorac Surg 83 2176 2181 17532418 10.1016/j.athoracsur.2007.02.006 (Pubitemid 46782667)
145. T.K. Waddell L. Bennett R. Kennedy T.R. Todd S.H. Keshavjee 2002 Heart-lung or lung transplantation for Eisenmenger syndrome J Heart Lung Transplant 21 731 737 12100899 10.1016/S1053-2498(01)00420-X (Pubitemid 34718178)
146. C.K. Choong S.C. Sweet T.J. Guthrie E.N. Mendeloff F.J. Haddad P. Schuler, et al. 2005 Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience J Thorac Cardiovasc Surg 129 661 669 15746752 10.1016/j.jtcvs.2004. 07.058 (Pubitemid 40311328)
147. G.P. Diller K. Dimopoulos C.S. Broberg M.G. Kaya U.S. Naghotra A. Uebing, et al. 2006 Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study Eur Heart J 27 1737 1742 16793921 10.1093/eurheartj/ehl116 (Pubitemid 44025362)
148. R. Radley-Smith P. Aurora 2006 Transplantation as a treatment for end-stage pulmonary hypertension in childhood Paediatr Respir Rev 7 117 122 1:STN:280:DC%2BD28zltlWgtw%3D%3D 16765297 10.1016/j.prrv.2006.03.004 (Pubitemid 43840889)